Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - Cellectar Biosciences, Inc.v452821_ex99-1.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________

 

FORM 8-K

___________________

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report: November 10, 2016
(Date of earliest event reported)

 

CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)

 

Delaware

1-36598

04-3321804

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

 

3301 Agriculture Drive
Madison, WI 53716
(Address of principal executive offices)

 

(608) 441-8120
(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

   

 

 

ITEM 7.01REGULATION FD DISCLOSURE

 

On November 10, 2016, we issued a press release announcing recent key accomplishments and our financial results for the third quarter of 2016, which ended September 30, 2016. The release further announced that management would host a conference call to review performance and results for the quarter on November 11, 2016, beginning at 8:30 A.M. EDT. A copy of the press release is furnished as Exhibit 99.1, and is incorporated by reference herein.

 

ITEM 9.01FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

Number   Title
99.1   Press release dated November 10, 2016, entitled “Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results”
     

 

 

 2 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:  November 10, 2016   CELLECTAR BIOSCIENCES, INC.  
       
       
  By: /s/  Chad J. Kolean   
    Name:  Chad J. Kolean  
    Title:  Vice President and Chief Financial Officer

 

 

 3 

 

 

EXHIBIT INDEX

 

Number   Title
99.1   Press release dated November 10, 2016, entitled “Cellectar Biosciences Announces Recent Key Accomplishments and Third Quarter 2016 Financial Results”
     

 

 

 4